Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

AviadoBio specializes in developing gene therapies for neurodegenerative diseases, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

AviadoBio

Capsida Biotherapeutics is a fully integrated next-generation gene therapy platform company that originated from groundbreaking research at Caltech. The company focuses on capsid engineering, cargo optimization, translational biology, process development and manufacturing, and clinical development, with the goal of creating customized therapies for both rare and common diseases across all ages.

Capsida Biotherapeutics

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences

Anavex Life Sciences Corp. is engaged in developing small molecule treatments aimed at addressing central nervous system (CNS) diseases, including Alzheimer's and Parkinson's diseases. Their approach focuses on targeting the Sigma-1 receptor and utilizing their SIGMACEPTOR™ platform.

Metric
Company Name	Anavex Life Sciences Corp.	AbbVie Inc.	AviadoBio	Capsida Biotherapeutics
Symbol	AVXL	ABBV
MSH ID	COM:ANAVEX	COM:ABBVIE	COM:AVIADOBIO	COM:CAPSIDA
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Drug Manufacturers - General	Biotechnology	Biotechnology
Country	US	US	GB
Stage
Employee Count	40	50K		51
Website	anavex.com	abbvie.com	aviadobio.com	capsida.com
LinkedIn
Founders

Metric
Market Cap	391.04M	296.91B
Enterprise Value
Monthly Web Traffic		1.18M	4.49K
Web Traffic Growth		0.51	0.18
Valuation
Raised Capital		15B

Metric
Revenue		54.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit		45.54B
EBITDA		18.10B
Operating Income		17.43B
Net Income		4.86B
EPS		2.75
Diluted EPS		2.74
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.72
Operating Profit Margin		0.27
EBITDA Margin		0.33
Net Profit Margin		0.11
Return on Equity		0.57
Return on Assets		0.04
Return on Capital Employed		0.15

COM:ANAVEX

Anavex Life Sciences Corp.

Last Close

9.02

22/11 21:00

Market Cap

731.79M

Beta: -

Volume Today

1.95M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		46.58
P/B Ratio		25.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		6.36
EV Multiple		17.44

Metric
Days Sales Outstanding		75.54
Days Payables Outstanding
Days Inventory Outstanding		102.41
Operating Cycle		181.71
Cash Conversion Cycle		179.57
Asset Turnover		0.40

Metric
Operating Cash Flow		22.84B
Free Cash Flow		22.06B
Cash Flow to Debt		0.38
Operating Cash Flow/Sales		0.42
Free Cash Flow Yield		0.08

Metric
Cash & Equivalents		12.81B
Accounts Receivable		66M
Inventory		4.10B
Goodwill		32.29B
Debt to Capitalization		0.91
Debt to Assets		0.45
Current Ratio		0.96
Quick Ratio		0.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue		0.14
SG&A to Revenue